Fig. 2: SARS-CoV-2 spike antibody prevalence stratified by demographic groups and vaccination status.

Mean antibody prevalence in the Routine Care (left column), and Urgent Care (right column) groups, measured between February 9th 2020 to July 18th 2022, and stratified by gender (A, B), age (C, D), race (E, F), and vaccination status at the time of sample collection (G, H) is shown. Gray color serves as visual contrast. Vertical dashed lines separate waves of SARS-CoV-2 infection in NYC. Samples were run in duplicate in a 2-step ELISA protocol. The mean of each graph is paired with a bootstrapped 95% confidence interval based on random resampling of results. A, B Gender stratification: males, females. C, D Categorical age levels: 18–44, 45–65, >65. Individuals <17 are not shown in this analysis. E, F Race/ethnicity stratification: White, Black, Asian, and Pacific Islander, Other, unknown. G, H The date on which the first FDA-authorized SARS-CoV-2 vaccine became available in NYC is indicated by the vertical doted line and syringe. Vaccination status was assessed at the time of sample collection and does not reflect vaccination rates in NYC or within our patient population. Alternating shaded areas in all graphs denote the five successive epidemiological waves of infection in NYC. Gray color and vertical dashed lines serve as visual contrast.